General References

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

U
Ubbink JB, Christianson A, Bester MJ et al. Folate status, homocysteine metabolism, and methylene tetrahydrofolate reductase genotype in rural South African blacks with a history of pregnancy complicated by neural tube defects. Metabolism 1999; 48:269-74.

Uberti D, Cenini G, Olivari L et al. Over-expression of amyloid precursor protein in HEK cells alters p53 conformational state and protects against doxorubicin. J Neurochem 2007; 103:322-33.

Ucar M, Mjörndal T, Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000; 22:441-57.

Uchaipichat V, Raungrut P, Chau N et al. Effects of ketamine on human UDP-glucuronosyltransferasrphine glucuronidation. Drug Metab Dispos 2011; 39:1324-8.

Uchida S, Shimada K, Misaka S et al. Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet 2010; 25:605-10.

Uchida S, Watanabe H, Nishio S et al. Altered pharmacokinetics and excessive hypotensive effect of candesartan in a patient with the CYP2C91/3 genotype. Clin Pharmacol Ther 2003; 74:505-8.

Uchida S, Yamada H, Li XD et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006; 46:1290-8.

Uchida T, Watanabe T, van Hoogdalem EJ, Higuchi S. In-vitro metabolism of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyltransferase, by liver microsomes in man. J Pharm Pharmacol 1996; 48:1049-56.

Uchida Y, Ohtsuki S, Katsukura Y et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011; 117:333-45.

Uchihashi S, Fukumoto H, Onoda M, Hayakawa H, Ikushiro S, Sakaki T. Metabolism of the c-Fos/activator protein-1 inhibitor T-5224 by multiple human UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 2011; 39:803-13.

Uchiyama M, Koda H, Fischer T et al. In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos 2011; 39:1311-9.

Udomsuk L, Jarukamjorn K, Putalun W, Sakuma T, Kawasaki Y, Nemoto N. Modified expression of aryl hydrocarbon receptor-related genes by deoxymiroestrol, a phytoestrogen, in mouse hepatocytes in primary culture. J Ethnopharmacol 2011; 137:902-8.

Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 2007; 17:1017-29.

Ueda K. ABC Proteins protect the human body and maintain optimal health. Biosci Biotechnol Biochem 2011; 75:401-9.

Ueda K, Ishitsu T, Seo T et al. Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity. Pharmacogenomics 2007; 8:435-42.

Ueda M, Hirokane G, Morita S et al. The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:486-91.

Ueda N, Yoshimura R, Umene-Nakano W et al. Grapefruit juice alters plasma sertraline levels after single ingestion of sertraline in healthy volunteers. World J Biol Psychiatry 2009; 10:832-5.

Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, Uno Y. Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 2011; 339:654-61.

Uehara S, Murayama N, Yamazaki H, Uno Y. A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica 2010; 40:621-9.

Uehlinger C, Crettol S, Chassot P et al. Increased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patients. J Clin Psychopharmacol 2007; 27:273-8.

Uejima E, Takahashi K, Morisaki T et al. Microsomal enzyme induction and clinical aggravation of porphyria: the evaluation of human urinary 6beta-hydroxycortisol/cortisol ratio as the index of hepatic CYP3A4 activity. J Clin Pharmacol 2002; 42:1374-9.

Uematsu M, Sakamoto O, Nishio T et al. A case surviving for over a year of renal tubular dysgenesis with compound heterozygous angiotensinogen gene mutations. Am J Med Genet 2006; 140:2355-60.

Uemura K, Kitagawa N, Kohno R et al. Presinilin 1 is involved in muturation and trafficking of N-cadherin to the plasma membrane. J Neurosci Res 2003; 74:184-91.

Ueng YF, Chen CC, Chung YT et al. Mechanism-based inhibition of cytochrome P450 (CYP)2A6 by chalepensin in recombinant systems, in human liver microsomes and in mice in vivo. Br J Pharmacol 2011; 163:1250-62.

Ueng YF, Don MJ, Jan WC, Wang SY, Ho LK, Chen CF. Oxidative metabolism of the alkaloid rutaecarpine by human cytochrome P450. Drug Metab Dispos 2006; 34:821-7.

Ueng YF, Hsieh CH, Don MJ. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole. Food Chem Toxicol 2005; 43:707-12.

Ueng YF, Tsai CC, Lo WS, Yun CH. Induction of hepatic cytochrome P450s by the herbal medicine Sophora flavescens extract in rats: impact on the elimination of theophylline. Drug Metab Pharmacokinet 2010; 25:560-7.

Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 2007; 97:145-51.

Ueno K. Gender differences in pharmacokinetics of anesthetics. Masui 2009; 58:51-8.

Ueno K, Tamamura A, Matsumoto K et al. Evaluation of mexiletine clearance in a Japanese population. Ann Pharmacother 2002; 36:241-5.

Ueshima Y, Tsutsumi M, Takase S, Matsuda Y, Kawahara H. Acetaminophen metabolism in patients with different cytochrome P-4502E1 genotypes. Alcohol Clin Exp Res 1996; 20(1 Suppl):25-8.

Ueta M, Sotozono C, Tokunaga K, Yabe T, Kinoshita S. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143:367-8.

Ueta M, Tokunaga K, Sotozono C et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008; 14:550-5.

Ueyama H, Koiwai O, Soeda Y et al. Analysis of the promoter of human bilirubin UDP-glucuronosyltransferase gene (UGT1*1) in relevance to Gilbert’s syndrome. Hepatology Research 1997; 9:152-63.

Ueyama J, Wang D, Kondo T et al. Toxicity of diazinon and its metabolites increases in diabetic rats. Toxicol Lett 2007; 170:229-37.

Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 2005; 44:1227-46.

Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103:572-85.

Ufer M, Dilger K, Leschhorn L et al. Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expression. Clin Pharmacol Ther 2008; 84:43-6.

Ufer M, Kammerer B, Kahlich R et al. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004; 34:847-59.

Ufer M, Mosyagin I, Muhle H et al. Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics 2009; 19:353-62.

Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G. Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 2004; 60:173-82.

Ugalde C, Triepels RH, Coenen MJ et al. Impaired complex I assembly in a Leigh syndrome patient with a novel missense mutation in the ND6 gene. Ann Neurol 2003; 54:665-9.

Uhart M, McCaul ME, Oswald LM, Choi L, Wand GS. GABRA6 gene polymorphism and an attenuated stress response. Mol Psychiatry 2004; 9:998-1006.

Uher R, Huezo-Diaz P, Perroud N et al. Genetic predictors of response to antidepressants in the GENDEP project. Pharmacogenomics J 2009; 9:225-33.

Uhr M, Grauer MT. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J Psychiatr Res 2003; 37:179-85. Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54:840-6.

Uhr M, Steckler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22:380-7.

Uhr M, Tontsch A, Namendorf C et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57:203-9.

Ujike H, Harano M, Inada T et al. Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis. Pharmacogenomics J 2003; 3:242-7.

Ujike H, Nomura A, Morita Y et al. Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study. J Clin Psychiatry 2008; 69:1416-22.

UK IBD Genetics Consortium et al. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 2009; 41:1330-4.

Ukaji M, Saito Y, Fukushima-Uesaka H et al. Genetic variations of VDR/NR1I1 encoding vitamin D receptor in a Japanese population. Drug Metab Pharmacokinet 2007; 22:462-7.

Ukkola O, Pérusse L, Chagnon YC, Després JP, Bouchard C. Interactions among the glucocorticoid receptor, lipoprotein lipase and adrenergic receptor genes and abdominal fat in the Québec Family Study. Int J Obes Relat Metab Disord 2001; 25:1332-9.

Ukkola O, Rankinen T, Weisnagel SJ et al C. Interactions among the alpha2-, beta2-, and beta3-adrenergic receptor genes and obesity-related phenotypes in the Quebec Family Study. Metabolism 2000; 49:1063-70.

Ukpebor J, Llabjani V, Martin FL, Halsall CJ. Sublethal genotoxicity and cell alterations by organophosphorus pesticides in MCF-7 cells: implications for environmentally relevant concentrations. Environ Toxicol Chem 2011; 30:632-9.

Ulgen MS, Ozturk O, Yazici M et al. Association between A/C1166 gene polymorphism of the angiotensin II type 1 receptor and biventricular functions in patients with acute myocardial infarction. Circ J 2006; 70:1275-9.

Ul-Haq Z, Mahmood U, Jehangir B. Ligand-based 3D-QSAR studies of physostigmine analogues as acetylcholinesterase inhibitors. Chem Biol Drug Des 2009; 74:571-81.

Ulrich AB, Standop J, Schmied BM, Schneider MB, Lawson TA, Pour PM. Expression of drug-metabolizing enzymes in the pancreas of hamster, mouse, and rat, responding differently to the pancreatic carcinogenicity of BOP. Pancreatology 2002; 2:519-27.

Ulrich AB, Standop J, Schmied BM, Schneider MB, Lawson TA, Pour PM. Species differences in the distribution of drug-metabolizing enzymes in the pancreas. Toxicol Pathol 2002; 30:247-53.

Ulrich CM, Bigler J, Sibert J et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum Mutat 2002; 20:409-10.

Ulrich CM, Bigler J, Sparks R et al. Polymorphisms in PTGS1 (=COX-1) and risk of colorectal polyps. Cancer Epidemiol Biomarkers Prev 2004; 13:889-93.

Ulrich CM, Whitton J, Yu JH et al. PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 2005; 14:616-9.

Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: a cross-section study in psychiatric patients. Pharmacopsychiatry 2005; 38:171-7.

Ulucan C, Cetintas V, Tetik A et al. Beta1 and beta2-adrenergic receptor polymorphisms and idiopathic ventricular arrhythmias. J Cardiovasc Electrophysiol 2008; 19:1053-8.

Ulvila J, Arpiainen S, Pelkonen O et al. Regulation of Cyp2a5 transcription in mouse primary hepatocytes: roles of hepatocyte nuclear factor 4 and nuclear factor I. Biochem J 2004; 381:887-94.

Ullrich M, Bundschu K, Benz PM et al. Identification of SPRED2 (sprouty-related protein with EVH1 domain 2) as a negative regulator of the hypothalamic-pituitary-adrenal axis. J Biol Chem 2011; 286:9477-88.

Um JY, Jang CH, Kim SJ et al. Steroid combination therapy and detoxification enzyme gene polymorphisms in sudden sensorineural hearing loss patients. Otol Neurotol 2011; 32:872-6.

Umannová L, Machala M, Topinka J et al. Benzo[a]pyrene and tumor necrosis factor-α coordinately increase genotoxic damage and the production of proinflammatory mediators in alveolar epithelial type II cells. Toxicol Lett 2011; 206:121-9.

Umans L, Serneels L, Overbergh L, Stas L, van Leuven F. alpha2-macroglobulin- and murinoglobulin-1- deficient mice. A mouse model for acute pancreatitis. Am J Pathol 1999; 155:983-93.

Umeda T, Mori H, Zheng H, Tomiyama T. Regulation of cholesterol efflux by amyloid beta secretion. J Neurosci Res 2010; 88:1985-94.

Umehara K, Shimokawa Y, Miyamoto G. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 2002; 25:682-5.

Umehara K, Shimokawa Y, Miyamoto G. Effect of probucol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2002; 25:1112-4.

Umehara K, Shimokawa Y, Miyamoto G. Effect of gamma-oryzanol on cytochrome P450 activities in human liver microsomes. Biol Pharm Bull 2004; 27:1151-3.

Umehara KI, Susaki Y, van Teylingen RH et al. Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. Eur J Drug Metab Pharmacokinet 2008; 33:211-23.

Umetani M, Shaul PW. 27-Hydroxycholesterol: the first identified endogenous SERM. Trends Endocrinol Metab 2011; 22:130-5.

Ung D, Nagar S. Variable sulfation of dietary polyphenols by recombinant human sulfotransferase (SULT) 1A1 genetic variants and SULT1E1. Drug Metab Dispos 2007; 35:740-6.

Ung D, Parkman HP, Nagar S. Metabolic interactions between prokinetic agents domperidone and erythromycin: an in vitro analysis. Xenobiotica 2009; 39:749-56.

Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 2002; 68:1055-8.

Unlü A, Ates NA, Tamer L, Ates C. Relation of glutathione S-transferase T1, M1 and P1 genotypes and breast cancer risk. Cell Biochem Funct 2008; 26:643-7.

Uno S, Dalton TP, Dragin N et al. Oral benzo[a]pyrene in Cyp1 knockout mouse lines: CYP1A1 important in detoxication, CYP1B1 metabolism required for immune damage independent of total-body burden and clearance rate. Mol Pharmacol 2006; 69:1103-14.

Uno S, Endo K, Ishida Y et al. CYP1A1 and CYP1A2 expression: comparing ‘humanized’ mouse lines and wild-type mice; comparing human and mouse hepatoma-derived cell lines. Toxicol Appl Pharmacol 2009; 237:119-26.

Uno T, Ohkubo T, Motomura S, Sugawara K. Effect of grapefruit juice on the disposition of manidipine enantiomers in healthy subjects. Br J Clin Pharmacol 2006; 61:533-7.

Uno T, Sugimoto K, Sugawara K, Tateishi T. The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers. J Clin Pharm Ther 2008; 33:67-73.

Uno T, Yasui-Furukori N. Effect of grapefruit juice in relation to human pharmacokinetic study. Curr Clin Pharmacol 2006; 1:157-61.

Uno Y, Hosaka S, Matsuno K et al. Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 2007; 466:98-105.

Uno Y, Iwasaki K, Yamazaki H, Nelson DR. Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 2011; 43:346-61.

Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). J Vet Med Sci 2009; 71:1653-6.

Uno Y, Matsuno K, Nakamura C, Utoh M, Yamazaki H. Identification and characterization of CYP2C18 in the cynomolgus macaque (Macaca fascicularis). J Vet Med Sci 2010; 72:225-8.

Uno Y, Matsushita A, Osada N et al. Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques. Drug Metab Dispos 2010; 38:209-14.

Uno Y, Matsushita A, Yamazaki H. CYP1B1 is polymorphic in cynomolgus and rhesus macaques. J Vet Med Sci 2011; 73:1229-31.

Uno Y, Sakamoto Y, Yoshida K et al. Characterization of six base pair deletion in the putative HNF1-binding site of human PXR promoter. J Hum Genet 2003; 48:594-7.

Uno Y, Uehara S, Kohara S, Murayama N, Yamazaki H. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab Dispos 2010; 38:1486-92.

Uno Y, Uehara S, Murayama N, Yamazaki H. CYP1D1, pseudogenized in human, is expressed and encodes a functional drug-metabolizing enzyme in cynomolgus monkey. Biochem Pharmacol 2011; 81:442-50.

Unoki H, Takahashi A, Kawaguchi T et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008; 40:1098-102.

Upadhya SC, Tirumalai PS, Boyd MR, Mori T, Ravindranath V. Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. Arch Biochem Biophys 2000; 373:23-34.

Uppstad H, Osnes GH, Cole KJ, Phillips DH, Haugen A, Mollerup S. Sex differences in susceptibility to PAHs is an intrinsic property of human lung adenocarcinoma cells. Lung Cancer 2011; 71:264-70.

Uppstad H, Øvrebø S, Haugen A, Mollerup S. Importance of CYP1A1 and CYP1B1 in bioactivation of benzo[a]pyrene in human lung cell lines. Toxicol Lett 2010; 192:221-8.

Upreti VV, Eddington ND. Fluoxetine pretreatment effects pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, ECSTASY) in rat. J Pharm Sci 2008; 97:1593-605.

Upthagrove AL, Nelson WL. Importance of amine pKa and distribution coefficient in the metabolism of fluorinated propranolol derivatives. Preparation, identification of metabolite regioisomers, and metabolism by CYP2D6. Drug Metab Dispos 2001; 29:1377-88.

Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics 2008; 5:458-69.

Urasaki Y, Laco G, Takebayashi Y, Bailly C, Kohlhagen G, Pommier Y. Use of camptothecin-resistant mammalian cell lines to evaluate the role of topoisomerase I in the antiproliferative activity of the indolocarbazole, NB-506, and its topoisomerase I binding site. Cancer Res 2001; 61:504-8.

Urayama KY, Wiencke JK, Buffler PA, Chokkalingam AP, Metayer C, Wiemels JL. MDR1 gene variants, indoor insecticide exposure, and the risk of childhood acute lymphoblastic leukemia. Cancer Epidemiol Biomarkers Prev 2007; 16:1172-7.

Urban TJ, Yang C, Lagpacan LL et al. Functional effects of protein sequence polymorphisms in the organic cation/ergothioneine transporter OCTN1 (SLC22A4). Pharmacogenet Genomics 2007; 17:773-82.

Urdaneta A, Siso A, Urdaneta B et al. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib. Brain Res Bull 2009; 80:56-61.

Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 2008; 9:410-8.

Urien S, Doz F, Giraud C et al. Developmental pharmacokinetics of etoposide in 67 children: lack of dexamethasone effect. Cancer Chemother Pharmacol 2011; 67:597-603.

Urquhart BL, Tirona RG, Kim RB. Nuclear receptors and the regulation of drug-metabolizing enzymes and drug transporters: implications for interindividual variability in response to drugs. J Clin Pharmacol 2007; 47:566-78.

Ursic D, Berginc K, Zakelj S, Kristl A. Influence of luminal monosaccharides on secretion of glutathione conjugates from rat small intestine in vitro. Int J Pharm 2009; 381:199-204.

Uruno A, Matsuda K, Noguchi N et al. Peroxisome proliferator-activated receptor-{gamma} suppresses CYP11B2 expression and aldosterone production. J Mol Endocrinol 2011; 46:37-49.

Urushino N, Yasuda K, Ikushiro S, Kamakura M, Ohta M, Sakaki T. Metabolism of 1alpha,25-dihydroxyvitamin D2 by human CYP24A1. Biochem Biophys Res Commun 2009; 384:144-8.

Ushikubi F, Okuma M, Kanaji K et al. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Thromb Haemost 1987; 57:158-64.

Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y. Sesquiterpenes and flavonol glycosides from Zingiber aromaticum and their CYP3A4 and CYP2D6 inhibitory activities. J Nat Prod 2004; 67:1079-83.

Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y. CYP3A4 and CYP2D6 inhibitory activities of Indonesian medicinal plants. Phytomedicine 2006; 13:67-73.

Usia T, Watabe T, Kadota S, Tezuka Y. Mechanism-based inhibition of CYP3A4 by constituents of Zingiber aromaticum. Biol Pharm Bull 2005; 28:495-9.

Usia T, Watabe T, Kadota S, Tezuka Y. Cytochrome P450 2D6 (CYP2D6) inhibitory constituents of Catharanthus roseus. Biol Pharm Bull 2005; 28:1021-4.

Usia T, Watabe T, Kadota S, Tezuka Y. Potent CYP3A4 inhibitory constituents of Piper cubeba. J Nat Prod 2005; 68:64-8.

Usia T, Watabe T, Kadota S, Tezuka Y. Metabolite-cytochrome P450 complex formation by methylenedioxyphenyl lignans of Piper cubeba: mechanism-based inhibition. Life Sci 2005; 76:2381-91.

Uslaner JM, Smith SM, Huszar SL et al. Combined administration of an mGlu2/3 receptor agonist and a 5-HT 2A receptor antagonist markedly attenuate the psychomotor-activating and neurochemical effects of psychostimulants. Psychopharmacology 2009; 206:641-51.

Uslu A, Ogus C, Ozdemir T, Bilgen T, Tosun O, Keser I. The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. BMB Rep 2010; 43:530-4.

Usmani KA, Cho TM, Rose RL, Hodgson E. Inhibition of the human liver microsomal and human cytochrome P450 1A2 and 3A4 metabolism of estradiol by deployment-related and other chemicals. Drug Metab Dispos 2006; 34:1606-14.

Usmani KA, Hodgson E, Rose RL. In vitro metabolism of carbofuran by human, mouse, and rat cytochrome P450 and interactions with chlorpyrifos, testosterone, and estradiol. Chem Biol Interact 2004; 150:221-32.

Usmani KA, Rose RL, Goldstein JA, Taylor WG, Brimfield AA, Hodgson E. In vitro human metabolism and interactions of repellent N,N-diethyl-m-toluamide. Drug Metab Dispos 2002; 30:289-94.

Usmani KA, Rose RL, Hodgson E. Inhibition and activation of the human liver microsomal and human cytochrome P450 3A4 metabolism of testosterone by deployment-related chemicals. Drug Metab Dispos 2003; 31:384-91.

Ustach CV, Huang W, Conley-LaComb MK et al. A novel signaling axis of matriptase/PDGF-D/ß-PDGFR in human prostate cancer. Cancer Res 2010; 70:9631-40.

Usui T, Hashizume T, Katsumata T, Yokoi T, Komuro S. In vitro investigation of the glutathione transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab Dispos 2011; 39:1303-10.

Usui T, Kuno T, Mizutani T. Induction of human UDP-glucuronosyltransferase 1A1 by cortisol-GR. Mol Biol Rep 2006; 33:91-6.

Usui T, Saitoh Y, Komada F. Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull 2003; 26:510-7.

Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. Am J Health Syst Pharm 2006; 63:2340-8.

Uto-Kondo H, Ayaori M, Ogura M et al. Coffee consumption enhances high-density lipoprotein-mediated cholesterol efflux in macrophages. Circ Res 2010; 106:779-87.

Utsunomiya K, Shinkai T, de Luca V et al. Genetic association between the dopamine D3 gene polymorphism (Ser9Gly) and schizophrenia in Japanese populations: evidence from a case-control study and meta-analysis. Neurosci Lett 2008; 444:161-5.

Uttamsingh V, Lu C, Miwa G, Gan LS. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 2005; 33:1723-8.

Uttayamakul S, Likanonsakul S, Manosuthi W et al. Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults. AIDS Res Ther 2010; 7:8.

Uusitupa MI, Karvonen MK, Pesonen U, Koulu M. Neuropeptide Y: a novel link between the neuroendocrine system and cholesterol metabolism. Ann Med 1998; 30:508-10.

Uyar OA, Kara M, Erol D, Ardicoglu A, Yuce H. Investigating paraoxonase-1 gene Q192R and L55M polymorphism in patients with renal cell cancer. Genet Mol Res 2011; 10:133-9.

Uzelac PS, Li X, Lin J et al. Dysregulation of leptin and testosterone production and their receptor expression in the human placenta with gestational diabetes mellitus. Placenta 2010; 31:581-8.

Uzma N, Kumar BS, Priyadarsini KI. Hepatoprotective, immunomodulatory, and anti-inflammatory activities of selenocystine in experimental liver injury of rats. Biol Trace Elem Res 2011; 142:723-34.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z